Patients who wish to consider this injectable regimen must be adults infected with HIV who are on a stable regimen and who are virologically suppressed (HIV-1 viral load < 50 copies per milliliter) with no history of treatment failure and with no known or suspected resistance to either rilpivirine or cabotegravir.